Frequently Asked Questions - Baricitinib’s Safety Profile

Classes Rheumatology Frequently Asked Questions - Baricitinib’s Safety Profile

Instructions

Please Sign in to your account to see the Class.

Introduction

Baricitinib’s safety profile has been evaluated in integrated safety datasets that incorporate long-term data including those from Phase 3 studies. In patients with moderate to sever active RA with exposure up to 5.5 years, Baricitinib has an acceptable safety profile in the context of demonstrated efficacy. Find out more about Baricitinib’s safety with Prof Patrick Durez and Prof.Eugen Feist.